Linked Life Data

18974627

Source:http://linkedlifedata.com/resource/pubmed/id/18974627

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-3-2
pubmed:abstractText
The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somatostatin receptors (SSTR). To correlate the expression of SSTR subtypes by reverse transcriptase-polymerase chain reaction (RT-PCR) with clinicopathological features and survival in a group of WDEC patients, 42 WDEC tissue specimens from 33 patients were analysed. All patients were treated with somatostatin analogues and had a median follow-up period of 45 months (range 6-196). Neither SSTR2 and SSTR5 expression nor Ki-67 level alone correlated with survival. A significantly better survival rate was observed in patients with tumours expressing SSTR2, SSTR5 and Ki-67 <2%, compared to those with SSTR2- and SSTR5-negative tumours and Ki-67 >or=2% (p < 0.038), with 5-year survival rates of 91 vs. 43%, respectively. Expression of SSTR2 and SSTR5 appears to play a positive prognostic role, possibly correlated with the high affinity that the available somatostatin analogues display for these 2 specific SSTR subtypes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1423-0194
pubmed:author
pubmed:copyrightInfo
(c) 2008 S. Karger AG, Basel.
pubmed:issnType
Electronic
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
223-30
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas.
pubmed:affiliation
Department of Digestive and Liver Disease, II School of Medicine, University La Sapienza, Roma, Italy. vito.corleto@uniroma1.it
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't